ABVC (ABVC BioPharma) Issuance of Debt: $0.55 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ABVC ABVC BioPharma Inc ABVC
17 GF Score
Price $1.15
! 1 Warning Sign
View Full Analysis

What is ABVC BioPharma Issuance of Debt?

ABVC BioPharma ABVC -0.43% 17 Issuance of Debt is $0.55 Mil as of Jun. 2026. GuruFocus rates ABVC with a GF Score™ of 17/100. The stock has 1 warning sign investors should review.

ABVC BioPharma's Issuance of Debt for the three months ended in Jun. 2026 was $0.00 Mil.

ABVC BioPharma's Issuance of Debt for the trailing twelve months (TTM) ended in Jun. 2026 was $0.55 Mil.

ABVC BioPharma Issuance of Debt Related Terms

ABVC BioPharma Issuance of Debt Historical Data

* Premium members only.

The historical data trend for ABVC BioPharma's Issuance of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ABVC BioPharma Issuance of Debt Chart

ABVC BioPharma Annual Data
Trend Sep16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Issuance of Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.24 0.59 1.46 0.94 0.34

ABVC BioPharma Quarterly Data
Jun21 Sep21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Issuance of Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.55 0.00 0.00
ABVC
17GF Score
ABVC BioPharma Inc ABVC
Issuance of Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ABVC BioPharma Issuance of Debt Calculation

Issuance of Debt represents all the cash inflow from debt, including both long-term debt and short-term debt.

Issuance of Debt for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.55 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Issuance of Debt →
What does a Issuance of Debt of $0.55 Mil mean?
ABVC BioPharma (ABVC) has a Issuance of Debt of $0.55 Mil as of Jun. 2026. Issuance of Debt is all the cash inflow from debt, including both long-term debt and short-term debt. View historical data on ABVC BioPharma and its competitors.
Is ABVC BioPharma's Issuance of Debt too high?
ABVC BioPharma's current Issuance of Debt is $0.55 Mil. Overall, ABVC BioPharma has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does ABVC BioPharma's Issuance of Debt compare to ALLR and MRKR?
ABVC BioPharma's Issuance of Debt of $0.55 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Issuance of Debt for a Biotechnology company?
A good Issuance of Debt depends on the Biotechnology industry context. However, Issuance of Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Issuance of Debt mean?
A high Issuance of Debt can signal that a stock is expensive relative to its fundamentals. Issuance of Debt is all the cash inflow from debt, including both long-term debt and short-term debt. View historical data on ABVC BioPharma and its competitors. ABVC BioPharma's current Issuance of Debt is $0.55 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ABVC BioPharma stock overvalued right now?
ABVC BioPharma (ABVC) has a current Issuance of Debt of $0.55 Mil. The current Issuance of Debt is $0.55 Mil. ABVC BioPharma's overall GF Score™ is 17/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Issuance of Debt calculated?
Issuance of Debt is calculated from a company's financial statements. For ABVC BioPharma (ABVC), the current Issuance of Debt is $0.55 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

ABVC BioPharma Business Description

Address 44370 Old Warm Springs Boulevard, Fremont, CA, USA, 94538
ABVC BioPharma Inc. is a clinical-stage biopharmaceutical company based in the United States that develops plant-derived therapeutics and medical devices. Its pipeline includes drug candidates targeting major depressive disorder (ABV-1504), attention-deficit/hyperactivity disorder (ABV-1505 and ABV-1601), and other indications, along with the Vitargus vitreous substitute (ABV-1701) and additional ophthalmic and oncology-related device programs. The company also conducts research through collaborations with academic and clinical institutions, including work in Taiwan and other Asian markets. ABVC generates limited revenue from licensing arrangements, research collaborations, and development-stage activities rather than from commercialized products, as most of its candidates remain in preclinical or clinical testing. Its strategy centers on advancing botanically based treatments intended to offer efficacy with reduced toxicity, and on partnering or out-licensing programs to fund further development.
17GF Score

Get the complete analysis for ABVC

Issuance of Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.15
Price